# Orthox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orthox

- Industry: Medical Devices & Equipment
- Headquarters: Abingdon, UK
- Website: www.orthox.com
- Total disclosed funding: $13M
- Latest round: Series A (Feb 9, 2022)
- Investors on record: 4

## About

Based in Abingdon, UK, and founded in 2008 by CEO Dr. Nick Skaer and co-founder Professor Oliver Kessler. Orthox Ltd. operates as a clinical-stage company that develops medical implants to repair damaged knee articular cartilage and other orthopedic injuries. In February 2022, Orthox Ltd. raised USD 12.5 million in a series A financing led by returning investor Parkwalk Advisors, with participation from another new investor, Additio Investment Group. 

Orthox Ltd. offers FibroFixTM is a biomaterial with a molecular structure, strength, and resilience that emulates human knee cartilage. It is based on Fibroin, a protein extracted from silk fibers, which Orthox processes using proprietary technology and targets treating injuries to the articular cartilage in the knee, which covers the ends of the femur (thigh bone) and tibia (shin bone).

Orthox Ltd. will use the series A funding to support further clinical trials of its lead product, FibroFixTM, at Southmead Hospital in Bristol, UK, and in Budapest, Hungary.

## Funding rounds

- Series A, Feb 9, 2022, $13M — Parkwalk Advisors, Perivoli Innovations, Oxford Investment Consultants, Additio Investment Group

## Investors

- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- Perivoli Innovations (https://capitalatlas.ai/funds/perivoli-innovations) — Series A
- Oxford Investment Consultants — Series A
- Additio Investment Group (https://capitalatlas.ai/funds/additio-investment-group) — Series A